KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Operating Income: 2018-2024

Historic Operating Income for Royalty Pharma (RPRX) over the last 7 years, with Dec 2024 value amounting to $1.3 billion.

  • Royalty Pharma's Operating Income fell 41.89% to $427.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 billion, marking a year-over-year decrease of 0.72%. This contributed to the annual value of $1.3 billion for FY2024, which is 13.38% down from last year.
  • As of FY2024, Royalty Pharma's Operating Income stood at $1.3 billion, which was down 13.38% from $1.5 billion recorded in FY2023.
  • Royalty Pharma's Operating Income's 5-year high stood at $1.6 billion during FY2020, with a 5-year trough of $307.1 million in FY2022.
  • For the 3-year period, Royalty Pharma's Operating Income averaged around $1.0 billion, with its median value being $1.3 billion (2024).
  • In the last 5 years, Royalty Pharma's Operating Income plummeted by 78.54% in 2022 and then soared by 385.94% in 2023.
  • Royalty Pharma's Operating Income (Yearly) stood at $1.6 billion in 2020, then decreased by 10.32% to $1.4 billion in 2021, then tumbled by 78.54% to $307.1 million in 2022, then surged by 385.94% to $1.5 billion in 2023, then declined by 13.38% to $1.3 billion in 2024.